A Hit Prioritization Strategy for Compound Library Screening Using LiP-MS and Molecular Dynamics Simulations Applied to KRas G12D Inhibitors

Avatar
Poster
Voice is AI-generated
Connected to paperThis paper is a preprint and has not been certified by peer review

A Hit Prioritization Strategy for Compound Library Screening Using LiP-MS and Molecular Dynamics Simulations Applied to KRas G12D Inhibitors

Authors

Absar, F.; Novy, B. C.; Nagy, E.; Petrotchenko, E. V.; Popov, K. I.; Cross, J. B.; Thapar, R.; Borchers, C. H.

Abstract

An important step in screening small molecule libraries for drug discovery is hit prioritization and validation to rule out false positives, which is usually performed using biochemical and biophysical assays. The development of orthogonal assays that are highly sensitive and can accelerate the hit-to-lead process is valuable. Limited proteolysis combined with mass spectrometry (LiP-MS) is a technique used to study changes in protein structure upon ligand binding. In LiP-MS, proteins are exposed to low concentrations of proteases under native conditions. The resulting proteolytic pattern is sensitive to protein structure at the cleavage site, which can change upon ligand binding. We characterized the interaction of small molecule inhibitors of the KRas G12D mutant oncoprotein by LiP-MS combined with molecular dynamics (MD). Intact mass spectrometry and top-down analysis were used to detect and identify KRas G12D cleavage products in the presence and absence of inhibitors, thereby locating the cleavage sites in the protein. Cleavage sites protected upon compound binding correlated well with the switch II binding site. The degree of cleavage depends on binding affinity and the presence of specific functional groups in the inhibitor structure. A comparison of MD simulations for the ligand-free and ligand-bound proteins revealed the atomistic mechanisms by which the cleavage sites, located in flexible and disordered regions, are stabilized upon compound binding. We suggest that LiP-MS combined with MD (LiP-MS-MD) could be valuable in small molecule screening campaigns and add to the repertoire of available methods for high-quality hit selection in early-stage drug discovery.

Follow Us on

0 comments

Add comment